Cebranopadol: A mixed-efficacy nociceptin/opioid receptor ligand for pain management—pharmacology, clinical evidence, safety, and abuse liability: A narrative review
Aminu Kano Academic Scholars Association Multidisciplinary Journal · 07.11.2026 · 6 (3) · 127-149
DOI: 10.64726/23m6x193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aminu Kano Academic Scholars Association Multidisciplinary Journal, online erschienen am 07.11.2026. Verfasst von Michael Oghenetega Afighor und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schmerzmanagement
Abstract (Originalsprache)
Pain remains a leading cause of disability worldwide, and the opioid crisis has intensified demand for analgesics that preserve efficacy while reducing respiratory depression, tolerance, dependence, and misuse. Cebranopadol is an investigational spiroindole ligand that binds NOP, MOP, KOP, and DOP receptors with mixed efficacy: full agonism at MOP and DOP, partial agonism at NOP and KOP. The therapeutic hypothesis is that NOP co-activation may modulate selected MOP-mediated adverse effects while contributing independent antinociception. This narrative review synthesises peer-reviewed preclinical and clinical evidence on cebranopadol's pharmacology, pharmacokinetics, efficacy, safety, and abuse liability, and explicitly distinguishes peer-reviewed findings from sponsor-reported development updates. Peer-reviewed Phase II studies support analgesic activity in chronic low-back pain, painful diabetic peripheral neuropathy, and cancer-related chronic pain; a non-inferiority comparison with prolonged-release morphine in cancer pain has been published. Phase III acute postoperative pain results (ALLEVIATE-1 and ALLEVIATE-2) are currently available only through company and trade-press sources and require confirmation in peer-reviewed publications. Controlled human abuse-potential studies report lower drug-liking scores than oxycodone, but these controlled conditions do not predict real-world misuse. Important uncertainties remain regarding the magnitude and clinical relevance of any respiratory-risk reduction, long-term safety, comparative effectiveness, generalisability, and post-marketing abuse liability. Cebranopadol represents a mechanistically distinctive investigational approach to analgesia, but its eventual clinical role will depend on transparent peer-reviewed reporting, regulatory review, and robust comparative and post-marketing evidence.
Zitieren
APA
Afighor, M. O., Adhekegba, O., Ezerioha, C. E., Ishokare, O. P., Chidebe, E. O., & Obo-Saka, S. (2026). Cebranopadol: A mixed-efficacy nociceptin/opioid receptor ligand for pain management—pharmacology, clinical evidence, safety, and abuse liability: A narrative review. Aminu Kano Academic Scholars Association Multidisciplinary Journal, 6(3), 127-149. https://doi.org/10.64726/23m6x193
Vancouver
Afighor MO, Adhekegba O, Ezerioha CE, Ishokare OP, Chidebe EO, Obo-Saka S. Cebranopadol: A mixed-efficacy nociceptin/opioid receptor ligand for pain management—pharmacology, clinical evidence, safety, and abuse liability: A narrative review. Aminu Kano Academic Scholars Association Multidisciplinary Journal. 2026;6(3):127-149. doi:10.64726/23m6x193
BibTeX
@article{Afighor2026,
author = {Afighor, Michael Oghenetega and Adhekegba, Odafe and Ezerioha, Chidi Emmanuel and Ishokare, Oghenevwegba Prisca and Chidebe, Emmanuel O. and Obo-Saka, Samuel},
title = {Cebranopadol: A mixed-efficacy nociceptin/opioid receptor ligand for pain management—pharmacology, clinical evidence, safety, and abuse liability: A narrative review},
journal = {Aminu Kano Academic Scholars Association Multidisciplinary Journal},
year = {2026},
volume = {6},
number = {3},
pages = {127--149},
doi = {10.64726/23m6x193}
}
EUVIMED